Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (261-270 of 386) with videos related to

Pageof 39
Sort By:
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1990
Collaborative investigation of variables in susceptibility testing of yeastsM A Pfaller, M G Rinaldi, J N Galgiani, et al.
American Journal of Clinical Pathology|July 16, 2011
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definitionAlastair I Bartlett, Jane Starcyznski, Tammy Robson, et al.
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
The Lancet. Oncology|October 25, 2020
How current assay approval policies are leading to unintended imprecision medicineRoberto Salgado, Andrew M Bellizzi, David Rimm, et al.
Journal of Clinical Pathology|December 10, 2014
Updated UK Recommendations for HER2 assessment in breast cancerEmad A Rakha, Sarah E Pinder, John M S Bartlett, et al.
Histopathology|October 23, 2009
Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-upJeremy St J Thomas, Gillian R Kerr, Wilma J L Jack, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection modelsF C Odds, F Van Gerven, A Espinel-Ingroff, et al.
American Journal of Clinical Pathology|September 19, 2009
Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISHJ M S Bartlett, Fiona M Campbell, Merdol Ibrahim, et al.
Breast Cancer Research and Treatment|February 13, 2017
The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancerJ S Thomas, A M Hanby, N Russell, et al.
Pageof 39

Showing results (261-270 of 386) with videos related to

Sort By:
Pageof 39
Plos One|April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerSherene Loi, Stefan Michiels, Jose Baselga, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1990
Collaborative investigation of variables in susceptibility testing of yeastsM A Pfaller, M G Rinaldi, J N Galgiani, et al.
American Journal of Clinical Pathology|July 16, 2011
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definitionAlastair I Bartlett, Jane Starcyznski, Tammy Robson, et al.
Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.
The Lancet. Oncology|October 25, 2020
How current assay approval policies are leading to unintended imprecision medicineRoberto Salgado, Andrew M Bellizzi, David Rimm, et al.
Journal of Clinical Pathology|December 10, 2014
Updated UK Recommendations for HER2 assessment in breast cancerEmad A Rakha, Sarah E Pinder, John M S Bartlett, et al.
Histopathology|October 23, 2009
Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-upJeremy St J Thomas, Gillian R Kerr, Wilma J L Jack, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection modelsF C Odds, F Van Gerven, A Espinel-Ingroff, et al.
American Journal of Clinical Pathology|September 19, 2009
Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISHJ M S Bartlett, Fiona M Campbell, Merdol Ibrahim, et al.
Breast Cancer Research and Treatment|February 13, 2017
The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancerJ S Thomas, A M Hanby, N Russell, et al.
Pageof 39